Shionogi
Multinational pharmaceutical company focused on discovery, development, regulatory approval and commercialization of therapeutics including antibiotics, antivirals and vaccines. Operates global R&D and clinical development programs, invests via corporate venture capital, develops digital health solutions, and runs sustainability programs addressing antimicrobial resistance and access to healthcare.
Industries
Nr. of Employees
Very Large (1000+)
Shionogi
Patents
Estimation system, estimation method, program, estimation model, brain activity training apparatus, brain activity training method, and brain activity training program
US-12616389-B2
View Details
Estimation system, estimation method, program, estimation model, brain activity training apparatus, brain activity training method, and brain activity training program
US-12616389-B2
View DetailsProducts
Antibiotic therapeutics
Development and commercialization of antibiotics targeting drug-resistant bacterial infections.
Vaccines and adjuvanted formulations
Vaccine candidates and formulations including adjuvant technologies for prophylactic use.
Antiviral therapeutics and prophylactics
Oral and parenteral antiviral therapeutics developed and advanced through clinical programs.
Topical dermatology formulations
Development and regulatory submissions for topical formulations for dermatological indications.
Digital therapeutic applications
Software-based therapeutic applications developed as adjunctive treatments for specific conditions.
Antibiotic therapeutics
Development and commercialization of antibiotics targeting drug-resistant bacterial infections.
Vaccines and adjuvanted formulations
Vaccine candidates and formulations including adjuvant technologies for prophylactic use.
Antiviral therapeutics and prophylactics
Oral and parenteral antiviral therapeutics developed and advanced through clinical programs.
Topical dermatology formulations
Development and regulatory submissions for topical formulations for dermatological indications.
Digital therapeutic applications
Software-based therapeutic applications developed as adjunctive treatments for specific conditions.
Services
Internal discovery programs and partner collaborations to identify and advance therapeutic candidates.
Design and execution of clinical trials, global patient enrollment and program management across development phases.
Preparation of regulatory dossiers, management of approvals and adverse event intake/reporting.
Development and deployment of digital therapeutics and digital transformation initiatives for healthcare delivery.
Strategic investments and alliance management to bring external innovations into development pipelines.
Internal discovery programs and partner collaborations to identify and advance therapeutic candidates.
Design and execution of clinical trials, global patient enrollment and program management across development phases.
Preparation of regulatory dossiers, management of approvals and adverse event intake/reporting.
Development and deployment of digital therapeutics and digital transformation initiatives for healthcare delivery.
Strategic investments and alliance management to bring external innovations into development pipelines.
Expertise Areas
- Drug discovery (antibiotics, antivirals, vaccines)
- Clinical development and trial management
- Vaccine and adjuvant development
- Antimicrobial resistance (AMR) research and stewardship
Key Technologies
- Drug discovery platforms
- Vaccine adjuvant technologies
- Clinical trial design and management platforms
- Real-world data (RWD) analytics
News & Updates
Regulatory approval in the U.S. for an oral antiviral indicated for prevention of COVID-19 following exposure.
Multiple regulatory approvals and supplemental indications granted in 2026 across jurisdictions including Japan, Australia and China.
Announcement of launch for a digital therapeutic application intended as an adjunctive treatment for pediatric ADHD in Japan.
SHIONOGI Group ranked highly in external assessments for activities addressing antimicrobial resistance.
Regulatory approval in the U.S. for an oral antiviral indicated for prevention of COVID-19 following exposure.
Multiple regulatory approvals and supplemental indications granted in 2026 across jurisdictions including Japan, Australia and China.
Announcement of launch for a digital therapeutic application intended as an adjunctive treatment for pediatric ADHD in Japan.
SHIONOGI Group ranked highly in external assessments for activities addressing antimicrobial resistance.